Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Becton Dickinson (BDX) has completed patient enrollment for its PREVENT clinical trial, which evaluates Phasix Mesh for preventing incisional hernias. This milestone brings the trial closer to data readout and potential regulatory review for what the company considers a groundbreaking product in this category. The trial's success could significantly impact Becton Dickinson's future product portfolio and revenue in the surgical hernia prevention market.
16,962 Shares in Becton, Dickinson and Company $BDX Acquired by Wealthfront Advisers LLC
Wealthfront Advisers LLC acquired a new stake of 16,962 shares in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, valued at approximately $2.57 million. Other institutional investors like Auto Owners Insurance Co, BlackRock Inc., and Vanguard Group Inc. also made significant moves in their BDX holdings. Analysts currently have a "Hold" rating on BDX with a consensus price target of $185.67, while company insiders have recently sold shares.
Flossbach Von Storch SE Sells 8,875 Shares of Becton, Dickinson and Company $BDX
Flossbach Von Storch SE reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.1% in the second quarter, selling 8,875 shares and bringing its total holdings to 116,897 shares valued at $17.69 million. Other institutional investors also adjusted their positions, and company insiders sold a total of 11,779 shares worth $1.97 million in the last ninety days. Becton, Dickinson and Company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $1.05 per share.
Danske Bank A S Decreases Stock Holdings in Becton, Dickinson and Company $BDX
Danske Bank A S significantly reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 17.1% in the second quarter, selling 47,003 shares and now owning 228,234 shares worth $34.54 million. Other institutional investors made various adjustments to their BDX holdings, while company insiders, including CEO Thomas E. Polen, Jr. and EVP Roland Goette, also sold shares. The article also provides financial metrics, recent earnings, dividend information, and analyst ratings for Becton, Dickinson and Company.
Foster & Motley Inc. Purchases New Position in Becton, Dickinson and Company $BDX
Foster & Motley Inc. has acquired a new stake of 5,452 shares in Becton, Dickinson and Company (NYSE:BDX), valued at approximately $825,000 during the second quarter. Other institutional investors also adjusted their positions in BDX, which saw insider stock sales from two EVPs totaling over $600,000. Analyst ratings for BDX are currently mixed, with an average "Hold" rating and a consensus price target of $185.67.
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors
Tandem Diabetes Care (TNDM) reported a Q2 2026 net loss of US$21.17 million despite sales of US$254.56 million, while reaffirming full-year sales guidance of US$1.07 billion to US$1.09 billion. The company is pivoting towards pharmacy-based pump distribution and new insulin delivery technologies, a strategic shift that could impact its revenue generation and long-term earnings profile. Investors are advised to consider the potential of this pharmacy expansion against competitive risks and shifting reimbursement terms.
Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?
Becton Dickinson (BDX) recently reported mixed third-quarter fiscal 2026 results with higher sales but lower net income compared to the previous year. The company is advancing its tissue regeneration pipeline and restructuring its quality leadership, which impacts its investment narrative. Investors are now assessing how these developments affect the company's long-term profitability and growth prospects, particularly concerning ongoing regulatory and quality challenges.
Did Stronger Sales and Quality Shuffle Just Shift Becton Dickinson's (BDX) Investment Narrative?
Becton Dickinson (BDX) recently reported mixed Q3 fiscal 2026 results with higher sales but lower net income. The company is advancing its tissue regeneration pipeline and reshaping its quality leadership. These developments refine BD's investment narrative, emphasizing the need for productivity and quality improvements to overcome cost pressures and regulatory issues.
Becton Dickinson and Co stock hits 52-week high at 187.5 USD
Becton Dickinson and Co (BDX) stock recently hit a 52-week high of $187.50, despite an InvestingPro analysis indicating it remains undervalued. This milestone follows a 19.65% increase over the past year and is supported by investor confidence. The company also reported strong third-quarter fiscal 2026 earnings, exceeding Wall Street expectations, and raised its full-year outlook.
M. Kulyk & Associates LLC Invests $3.84 Million in Becton, Dickinson and Company $BDX
M. Kulyk & Associates LLC recently acquired a new stake worth approximately $3.84 million in Becton, Dickinson and Company (NYSE:BDX) during the second quarter. This move is part of broader institutional investment activity, with several other firms significantly increasing their holdings in the medical instruments supplier. Despite some insider selling, analysts maintain a "Hold" consensus rating for BDX, with a target price of $185.67.
What's Going On With Becton Dickinson Stock Wednesday?
Becton, Dickinson and Company (NYSE: BDX) saw its stock rise about 3% on Wednesday after the FDA announced the company issued a correction for specific convenience kits containing recalled sodium chloride ampules from Huons Co., Ltd. Patients could be exposed to endotoxins or other contaminants, though no deaths or serious injuries have been reported. Analysts maintain a "Buy" consensus rating on Becton Dickinson stock, despite some technical indicators suggesting overbought conditions.
Pallas Capital Advisors LLC Takes $920,000 Position in Becton, Dickinson and Company $BDX
Pallas Capital Advisors LLC has acquired a new position of 6,076 shares, valued at approximately $920,000, in Becton, Dickinson and Company (BDX). This comes as institutional investors collectively own 86.97% of BDX. The company recently reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $1.05 per share.
Becton, Dickinson and Company $BDX Shares Sold by Great Lakes Advisors LLC
Great Lakes Advisors LLC decreased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 14.8% in the second quarter, selling 35,818 shares and retaining 206,911 shares worth approximately $31.31 million. Other institutional investors made various changes to their stakes in the company, with hedge funds and institutional investors collectively owning 86.97% of the stock. Insiders also sold shares, totaling 11,779 shares valued at $1,974,669 over the last quarter, reducing their overall ownership to 0.40%.
Deutsche Bank AG Purchases Shares of 1,349,544 Becton, Dickinson and Company $BDX
Deutsche Bank AG has acquired a significant new stake in Becton, Dickinson and Company (NYSE:BDX), purchasing over 1.3 million shares valued at approximately $204 million. This move is part of broader institutional investor activity, with hedge funds collectively owning 86.97% of the company's stock. The article also details recent insider stock sales, analyst ratings, financial performance, and dividend information for Becton, Dickinson and Company.
BlackRock Inc. Purchases Shares of 24,592,166 Becton, Dickinson and Company $BDX
BlackRock Inc. recently acquired a new stake of 24,592,166 shares in Becton, Dickinson and Company (NYSE:BDX), valued at approximately $3.72 billion, representing about 8.93% of the company. The article also details recent analyst ratings, with a consensus "Hold" rating and an average price target of $185.67, alongside insider selling activity and the company's latest financial performance and dividend announcement. Becton, Dickinson and Company reported strong earnings for the last quarter, beating consensus estimates, and announced a quarterly dividend of $1.05 per share.
BD appoints Gary Sorsher as EVP and chief quality officer
BD (Becton, Dickinson and Company) has announced the appointment of Gary Sorsher as Executive Vice President and chief quality officer, effective September 8. Sorsher brings over 30 years of experience in the medtech industry, previously serving as chief quality officer at Edwards Lifesciences. This appointment follows several other leadership changes at BD over the past year, including a new CFO and changes in segment presidents.
Nuance Investments LLC Acquires Shares of 96,615 Becton, Dickinson and Company $BDX
Nuance Investments LLC has acquired a new position of 96,615 shares in Becton, Dickinson and Company (NYSE:BDX), valued at approximately $14.62 million, making it their 12th largest holding. Other institutional investors like Auto Owners Insurance Co, Vanguard Group Inc., and BlackRock Inc. have also significantly adjusted their stakes in the medical instruments supplier. The article also details Becton, Dickinson and Company's recent financial performance, dividend announcement, insider stock sales, and current analyst ratings.
Plato Investment Management Ltd Purchases Shares of 11,485 Becton, Dickinson and Company $BDX
Plato Investment Management Ltd recently acquired 11,485 shares of Becton, Dickinson and Company (NYSE:BDX) valued at approximately $1.73 million in the second quarter. Other institutional investors have also adjusted their holdings in BDX. The article also provides recent analyst ratings, stock performance data, dividend announcements, and details on insider selling activities for Becton, Dickinson and Company.
Commerzbank Aktiengesellschaft FI Invests $2.39 Million in Becton, Dickinson and Company $BDX
Commerzbank Aktiengesellschaft FI has initiated a new position in Becton, Dickinson and Company (NYSE:BDX), acquiring shares valued at approximately $2.39 million. This investment comes amidst various other institutional investors adjusting their stakes in the medical instruments supplier, with several analysts also updating their price targets and ratings for BDX. The company recently announced a quarterly dividend and reported earnings that surpassed analyst expectations, though insider selling activity has also been noted.
Flputnam Investment Management Co. Takes $1.52 Million Position in Becton, Dickinson and Company $BDX
Flputnam Investment Management Co. recently acquired a $1.52 million stake in Becton, Dickinson and Company (BDX) during the second quarter, purchasing 10,080 shares. Institutional investors collectively own 86.97% of the company. Becton, Dickinson and Company exceeded analyst expectations with its recent earnings, reporting $4.98 billion in revenue and $3.23 EPS, while also maintaining its fiscal 2026 EPS guidance.
7,783 Shares in Becton, Dickinson and Company $BDX Purchased by Global Retirement Partners LLC
Global Retirement Partners LLC has purchased 7,783 shares of Becton, Dickinson and Company (BDX) for approximately $1.18 million, initiating a new position in the medical instruments supplier. BDX reported strong quarterly EPS and revenue growth, reaffirmed its fiscal 2026 EPS guidance, and declared a quarterly dividend. Despite insider sales totaling nearly $2 million, analysts maintain a "Hold" rating with an average price target of $185.67 for the stock.
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
BD (Becton, Dickinson and Company) has announced the appointment of Gary Sorsher as executive vice president and chief quality officer, effective September 8. Sorsher brings over 30 years of experience in leading quality organizations within MedTech companies, including his most recent role as chief quality officer at Edwards Lifesciences. Concurrently, Jeff Silvestri, current senior vice president, global head of quality, will retire in October after more than 25 years with the company.
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
BD (Becton, Dickinson and Company) announced the appointment of Gary Sorsher as executive vice president and chief quality officer, effective September 8. Sorsher brings over 30 years of experience in leading quality organizations in MedTech. Additionally, Jeffrey Silvestri, the current senior vice president and global head of quality, will retire in October after more than 25 years with the company.
Beverly Hills Private Wealth LLC Takes $3.35 Million Position in Becton, Dickinson and Company $BDX
Beverly Hills Private Wealth LLC has acquired a new position of 22,156 shares in Becton, Dickinson and Company (NYSE:BDX), valued at approximately $3.35 million. Other institutional investors also adjusted their holdings in the medical instruments supplier. The article also provides analyst ratings, stock performance data, recent earnings results, dividend announcements, and insider trading activity for Becton, Dickinson and Company.
Jeffrey Silvestri to Retire as Senior Vice President, Global Head of Quality of Becton, Dickinson and Company in October 2026
Jeffrey Silvestri, Senior Vice President and Global Head of Quality at Becton, Dickinson and Company, is set to retire in October 2026 after 25 years with the company. During his tenure, Silvestri played a significant role in enhancing BD's quality framework and capabilities across its operations. This announcement follows Becton, Dickinson and Company's recent appointment of Gary Sorsher as Executive Vice President and Chief Quality Officer, effective September 8, 2026.
PRVA|Privia Health Group Inc|Price:22.000|Chg%:+0.240
This article provides a detailed overview of Privia Health Group Inc (PRVA) stock, including its current price, market data, key figures, and financial performance metrics. It also features a "TradingKey Stock Score," analyst ratings with a target price, and a company profile outlining its business model and shareholder information. The stock currently has an overall "Buy" rating from analysts with a significant upside potential.
SFE Investment Counsel Invests $2.67 Million in Becton, Dickinson and Company $BDX
SFE Investment Counsel recently invested $2.67 million in Becton, Dickinson and Company (BDX), acquiring 17,614 shares in the second quarter. Institutional investors own 86.97% of the company, and analysts have a "Hold" rating with an average price target of $185.67. BDX exceeded quarterly earnings expectations, reporting $3.23 EPS and $4.98 billion in revenue, and declared a quarterly dividend of $1.05.
90,788 Shares in Becton, Dickinson and Company $BDX Acquired by Oppenheimer Asset Management Inc.
Oppenheimer Asset Management Inc. has acquired 90,788 shares of Becton, Dickinson and Company (NYSE:BDX) valued at approximately $13.7 million during the second quarter. The medical instruments supplier reported strong quarterly earnings, beating analyst estimates, and maintained its fiscal 2026 EPS guidance. While institutional investors own a significant portion of the company, insiders have recently sold shares, and analysts generally rate the stock as "Hold" with an average price target of $185.67.
555,953 Shares in Becton, Dickinson and Company $BDX Bought by Everett Harris & Co. CA
Everett Harris & Co. CA has purchased 555,953 shares of Becton, Dickinson and Company (NYSE:BDX) in the second quarter, making it their 21st largest holding valued at approximately $84.13 million. Other institutional investors have also adjusted their positions, and 86.97% of the stock is held by institutional investors. Analyst ratings for BDX are mixed, with a consensus "Hold" rating and a target price of $185.67, while recent insider sales have also been noted.
Bryn Mawr Trust Advisors LLC Purchases Shares of 46,332 Becton, Dickinson and Company $BDX
Bryn Mawr Trust Advisors LLC acquired 46,332 shares of Becton, Dickinson and Company (BDX) in the second quarter, valuing their new stake at approximately $7.0 million. This comes as institutional investors collectively own 86.97% of BDX, which recently exceeded quarterly earnings expectations with $3.23 EPS and $4.98 billion in revenue. The company also maintained its fiscal 2026 EPS guidance and declared a quarterly dividend of $1.05, while analysts hold a consensus "Hold" rating with an average price target of $185.67.
Is West Pharmaceutical Services (WST) Undervalued After Its Run to $349.42?
West Pharmaceutical Services (WST) has seen significant share price appreciation over the past year, currently trading at $349.42. While analysts project a fair value of around $404, suggesting it might be undervalued, the company's P/E ratio is higher than industry and peer averages. The potential for growth from GLP-1 related revenues and operational efficiencies are key factors in its valuation, though risks like tariffs and demand uncertainty exist.
Insider Selling: Becton, Dickinson and Company (NYSE:BDX) CEO Sells $768,120.00 in Stock
Becton, Dickinson and Company's CEO, Thomas Polen, Jr., sold 4,152 shares of BDX stock worth $768,120 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct ownership by 3.63%. This sale occurred as the company's shares rose 0.7% to $183.16, near its 52-week high, following better-than-expected quarterly earnings and revenue growth. The company also declared a quarterly dividend of $1.05 per share, yielding 2.3%, while analysts maintain a "Hold" rating with a consensus price target of $185.67.
Becton Dickinson (BDX) CEO exercises 43,278 SARs and disposes shares under 10b5-1 plan
Becton Dickinson & Co. Chairman, CEO, and President Thomas E. Polen Jr. exercised 43,278 Stock Appreciation Rights (SARs) on August 13, 2026, receiving common shares. Subsequently, he returned 39,126 shares to the issuer and sold 4,152 shares at $185.00 each. These transactions were conducted according to a Rule 10b5-1 plan established on March 2, 2026.
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services (WST) stock has seen a significant rally, surging 38.1% since the end of March, driven by strong organic revenue growth and increased adjusted EPS. The company benefits from high demand for its proprietary products, particularly those used in biologics, biosimilars, and GLP-1 therapies, alongside improvements in manufacturing productivity and compliance upgrades. Despite potential near-term execution risks and competitive pressures, WST maintains a favorable growth outlook.
Why Is Becton Dickinson (BDX) Getting Fresh Attention Today?
Becton Dickinson (BDX) is gaining attention after completing enrollment in its PREVENT clinical trial for Phasix Mesh, a significant step towards future U.S. regulatory submission. The stock has seen strong short-term gains, up over 20% in the last 30 days, raising questions about whether this reflects pipeline progress or over-optimistic sentiment. Despite a current undervaluation narrative, risks remain concerning trade headwinds or the potential costs of its Biosciences and Diagnostic Solutions separation.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has increased its 2026 earnings outlook after a strong second quarter, partially boosted by a one-time tariff refund. The company faces a $6 million headwind from rising memory-chip costs but plans to offset this with operational discipline and cost control. Despite a "Strong Sell" Zacks Rank, the stock shows favorable growth, value, and momentum characteristics.
Becton Dickinson (BDX) Is Up 6.6% After Strong Q3 And Higher 2026 Outlook Has The Bull Case Changed?
Becton, Dickinson and Company (BDX) reported strong third-quarter fiscal 2026 results, with sales increasing to US$4,983 million and updated full-year guidance expecting low single-digit GAAP revenue growth. This performance, along with a new collaboration for a semaglutide pen, supports the company's focus on medical technology and injectable therapies. However, net income fell, and analysts note potential risks from regulatory pressures and cost containment, though some project a significant upside to the current stock price.
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
West Pharmaceutical Services, Inc. (WST) shares have risen 17.2% in the last three months, driven by strong growth in its High-Value Product (HVP) components and improved operating margins. The company's raised 2026 revenue and earnings outlook further supports its positive trajectory, despite its premium valuation compared to industry averages. While HVP demand is robust, slower growth in Standard Products and West Vantage, along with execution risks, pose challenges for continued upside.
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
Omnicell (OMCL) has raised its 2026 earnings outlook after a strong second quarter, though a significant portion of the profit improvement came from a one-time tariff refund. The company faces increased memory-chip costs expected to impact gross margins but plans to leverage cost control and operating efficiency to absorb these pressures. Omnicell's updated guidance also includes widened product bookings and a reduction in annual recurring revenue expectations due to slower development of certain opportunities and lengthy hospital approval cycles.
Becton Dickinson EVP Roland Goette sells $440,887 in stock
Roland Goette, EVP at Becton Dickinson & Co (NYSE:BDX), sold 2,438 shares of company stock for $440,887 on August 11, 2026. Despite this insider sale, InvestingPro analysis suggests the stock is undervalued with potential upside. The transaction follows Becton Dickinson's strong Q3 fiscal 2026 results, which surpassed Wall Street expectations for earnings and revenue.
Becton Dickinson EVP Roland Goette sells $440,887 in stock
Roland Goette, EVP at Becton Dickinson & Co (NYSE:BDX), sold 2,438 shares of company stock for $440,887 on August 11, 2026. Despite the insider sale, InvestingPro analysis suggests the stock is undervalued with potential upside. This transaction follows Becton Dickinson's strong third-quarter fiscal 2026 results, where the company surpassed Wall Street expectations for earnings and revenue and raised its full-year outlook.
Citigroup Adjusts Price Target on Becton Dickinson and Co. to $208 From $204, Maintains Buy Rating
Citigroup has raised its price target for Becton Dickinson and Co. (BDX) from $204 to $208, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook by the analyst firm on the medical technology company. The article also provides a brief overview of Becton Dickinson's business segments and recent analyst activity.
RBC Adjusts PT on Becton Dickinson and Co. to $190 From $180, Keeps Sector Perform Rating
RBC has increased its price target for Becton Dickinson and Co. (BDX) to $190 from $180, while maintaining a Sector Perform rating on the stock. This adjustment reflects RBC's updated outlook on the medical technology company. The article notes this update from MT Newswires.
Becton, Dickinson and Company $BDX Shares Purchased by Handelsbanken Fonder AB
Handelsbanken Fonder AB increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 32.7% in the second quarter, now owning 170,572 shares valued at $25.81 million. Other institutional investors like Auto Owners Insurance Co and Vanguard Group Inc. also significantly modified their holdings. Insider transactions show CEO Thomas E. Polen, Jr. and EVP Michael David Garrison selling shares, while analysts have a mixed outlook on the stock with an average "Hold" rating and a target price of $185.00.
Becton, Dickinson and Company (NYSE:BDX) EVP Roland Goette Sells 2,438 Shares
Becton, Dickinson and Company's EVP Roland Goette sold 2,438 shares of BDX stock for approximately $440,888, reducing his holdings by 14.1%. The company recently reported strong quarterly earnings, beating estimates with adjusted EPS of $3.23 and a 5.4% year-over-year revenue increase to $4.98 billion. Despite a consensus "Hold" rating from analysts, the stock trades near its 12-month high, and the company declared a quarterly dividend of $1.05.
Becton Dickinson (NYSE: BDX) EVP Roland Goette sells 2,438 shares at $180.84
Becton Dickinson's EVP and President, EMEA, Roland Goette, sold 2,438 shares of common stock at $180.84 per share on August 11, 2026. These shares were acquired through the company's Global Share Investment Program. Following the sale, Goette directly holds 14,856 shares and indirectly holds 1,779 shares through a GSIP Trust.
Axogen (AXGN) Is Up 5.4% After Raising 2026 Revenue Outlook Despite Ongoing Losses – Has The Bull Case Changed?
Axogen (AXGN) saw its stock rise by 5.4% after reporting Q2 2026 sales of US$69.73 million and a net loss of US$1.52 million, alongside raising its full-year 2026 revenue outlook to at least US$279 million. This increased guidance signals management's confidence in demand for its nerve repair portfolio despite ongoing losses, while the company continues to invest heavily in capacity and commercialization. The article explores how this updated outlook impacts Axogen's investment narrative, noting its dependence on a single biologic portfolio and the potential influence of regulatory and reimbursement pressures.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have dropped 20.1% in the past month despite raising its 2026 profit outlook, due to concerns over bookings timing, recurring-revenue growth, rising component costs, and the pace of its product refresh. While the company's Q2 2026 earnings beat estimates, new pressures from memory-chip costs and a slower-than-expected refresh cycle are affecting margins and revenue predictability. Despite a low valuation, the Zacks Rank currently signals caution due to short-term uncertainties.
UBS Adjusts Becton Dickinson and Co. PT to $205 From $190, Maintains Buy Rating
UBS has increased its price target for Becton Dickinson and Co. (BDX) to $205 from $190, while reiterating a "Buy" rating on the stock. This adjustment reflects a positive outlook from the analyst firm on the medical technology company. The article also lists recent analyst adjustments and company news, indicating ongoing market activity around Becton Dickinson.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell (OMCL) shares have
